The high expression of CD99 on the cell surface and its crucial role in sustaining tumor malignancy are the two primary reasons why it has garnered significant interest over the years for developing new targeted therapies using mAbs for tumors that overexpress CD99. Here, CD99 is linked to neoplasm.